Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


biOasis Technologies Inc.

Latest From Sound Pharmaceuticals Inc.

Decibel Therapeutics: Protect. Repair. Restore.

Emerging Company Profile: Decibel Therapeutics, a Boston-based company focused on developing therapies for hearing loss, started adding its voice in an emerging development space in 2015, with the aim of becoming "the premier hearing therapies company." With ongoing research and preclinical candidates for hearing loss, Decibel is looking to secure a beneficial collaboration that will bump up its profile and give it the funding it needs to move forward.

StartUps and SMEs Research & Development

Tech Transfer Deals, April 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly review of licensing agreements between companies and universities or other research institutions in the In Vitro Diagnostics, Medical Device, and Pharmaceutical sectors. This month’s column covers deals announced February through March 2016.

BioPharmaceutical Medical Device

Sound Pharmaceuticals' hearing loss drug success in Phase II

Privately held, biopharmaceutical company Sound Pharmaceuticals (SPI) has released positive data Phase II data for its sensorineural hearing loss drug SPI-1005.

Lilly lends Audion its ears and gives it some cash

Eli Lilly has made a move into hearing loss treatments with an investment in private US biopharmaceutical company Audion Therapeutics.

Orthopedics Switzerland
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Cancer
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • biOasis Technologies Inc.
  • Senior Management
  • Rob Hutchison, Chmn. & CEO
    Judi Dalling, CFO
    Kim Elton, PhD, Dir., Mktg.
    Reinhard Gabathuler, PhD, Chief Scientist
  • Contact Info
  • biOasis Technologies Inc.
    Phone: (604) 295-7014
    130-10691 Shellbridge Way
    Richmond, V6X 2W8